免疫检查点阻断与肝癌化疗栓塞  

Immune checkpoint inhibition and chemoembolization of hepatocellular carcinoma

作　　者：张利捷 梁斌 ZHANG Lijie;LIANG Bin(Department of Radiology,Affiliated Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei Province 430022,China)

机构地区：[1]华中科技大学同济医学院附属协和医院放射科,武汉430022

出　　处：《介入放射学杂志》2020年第4期419-422,共4页Journal of Interventional Radiology

基　　金：国家自然科学基金面上项目(81771950)。

摘　　要：肝癌化疗栓塞通过动脉内灌注化疗药和阻断肿瘤血供诱导大量肿瘤细胞死亡,但它对肿瘤免疫的影响尚不明确。免疫检查点抑制疗法是目前肿瘤免疫治疗的主导方法,对某些特定癌症疗效显著,但并不是对所有癌症普遍有效。早期研究表明免疫检查点阻断与消融或栓塞联合治疗肝癌具有协同抗肿瘤作用。本文就肝癌免疫学特点、免疫检查点抑制剂及其与化疗栓塞联合治疗作一综述。Through intra-arterial infusion of chemotherapeutic drugs and blocking tumor blood supply, hepatic chemoembolization induces substantial tumor cell death, but its effect on tumor immunity remains unclear. At present, immune checkpoint inhibition therapy is the leading method of tumor immunotherapy, which has a significant effect on certain cancers, although it is not effective for all cancers. Early studies have shown that immune checkpoint inhibition therapy combined with ablation or embolization has synergistic antineoplastic effect on hepatocellular carcinoma(HCC). This article aims to make a comprehensive review about the immunological characteristics, the immune checkpoint inhibitor and its combination therapy with the chemoembolization of HCC.

关 键 词：化疗栓塞 免疫检查点 程序性细胞死亡蛋白1 细胞毒T淋巴细胞相关抗原4 肝细胞癌 

分 类 号：R735.7[医药卫生—肿瘤]